Roivant completed the acquisition by Roche of Telavant for $7.1 billion. Telavant owns RVT-3101, a therapy for inflammatory bowel disease. Roivant previously owned 75% of Telavant’s shares. An extra $150 million cash payment will be made after a near-term milestone. The acquisition aims to advance RVT-3101’s development across multiple indications, empowering Roche to enhance treatments for inflammatory and fibrotic diseases.
Roivant (Nasdaq: ROIV) announced today the completion of the previously announced acquisition by Roche (SIX: RO, ROG; OTCQX: RHHBY) of Telavant, for an upfront payment of approximately $7.1 billion. Telavant holds the rights in the US and Japan to RVT-3101, a promising new therapy in development for people suffering from inflammatory bowel disease, including ulcerative colitis and Crohn’s disease. Prior to the closing of the transaction, Roivant owned 75% of the issued and outstanding shares of common stock and preferred stock of Telavant, on an as-converted basis. An additional payment of $150 million in cash is payable upon the completion of a near-term milestone.
“We are pleased to announce the timely completion of the Telavant acquisition, and I am deeply grateful to everyone at Roivant and Telavant who worked tirelessly to develop RVT-3101, prepare for Phase 3, and execute this transaction. We look forward to seeing Roche continue the rapid development of RVT-3101 across multiple indications and ultimately transform the lives of patients with inflammatory and fibrotic diseases,” said Mayukh Sukhatme, M.D., President and Chief Investment Officer at Roivant. “This transaction enables us to continue doing what we do best, at even greater scale: work creatively side by side with our partners on programs that could generate significant impact for patients in areas of high unmet need.”
Additional information on the transaction can be found in the transaction announcement.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
Freshfields Bruckhaus Deringer LLP acted as legal counsel to Roivant.
Source: Bio Space
